Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus
Glucagon-like peptide-1 receptor agonists are similar to the GLP-1 hormone, which is secreted in the gastrointestinal tract in response to eating
It synthesizes data from early foundational studies to the most recent 2024 investigations into fusion peptides, examining the peptides biochemistry, its controversial but documented effects on sleep and hormones, and the regulatory challenges that currently define its status as an unauthorized substance in major jurisdictions
Expected Results and Timeline for Visceral Fat Reduction Clinical trial data provide evidence for the timeline and magnitude of weight loss with GLP-1 receptor agonists, though individual responses vary considerably
Another study, published in The Lancet, found that body weight and body composition were maintained one year after the termination of GLP-1 medications through the use of supervised exercise, in contrast to weight regain after the termination of treatment with obesity pharmacotherapy alone